|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.102 - 0.115|
|52 Week Range||0.043 - 0.282|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2018 - Nov 19, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.13|
This conference will address the state of science in pain management, characterize the epidemiology of the opioid epidemic, and identify actions that can be taken to respond to this crisis. Brady Granier, CEO, President, and Director of BioCorRx, stated, “We look forward to engaging with top thought leaders, as well as state and federal officials at the National Opioid Crisis Management Congress next week. Millions of Americans are suffering from opioid use disorder and the BioCorRx® Recovery Program is an ideal solution available now for many of those suffering, as it combines medications like naltrexone with cognitive behavioral therapy (CBT) and peer recovery support.
ANAHEIM, CA, Sept. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that actor Jeremy Miller appeared on Omaha, Nebraska’s local news channel, KETV NewsWatch ABC 7 Chronicle, on September 9, 2018, supporting the BioCorRx® Recovery Program. The I Got Sober treatment center, located in Omaha, Nebraska, utilizes the BioCorRx® Recovery Program to assist in treating their patients suffering from substance use disorder.
BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2018. In June, BioCorRx® announced it has completed a capital raise of $1.1 million.
BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a general update on BICX102, the Company’s sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. The company previously announced that a grant application was submitted to the National Institutes of Health (NIH) in May for the development of BICX102. This specific grant opportunity, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3), was created as a result of the current opioid epidemic.
PHOENIX, Ariz., July 24, 2018-- Uptick Newswire, today announced the return of BradyGrainer, CEO of BioCorRX Inc. to Uptick Newswire’ s Stock Day podcast with Everett Jolly. The Company is a developer ...
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Biocorrx, Inc. (OTCQB: BICX) and Repro-Med Systems, Inc. (OTCQX: ...